Physician profile
Tonia Soper
NPI 1720863814
$2,224.37
in general payments reported to CMS, 2019-2025
14 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $139 · 2024: $991 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $474.43 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $408.84 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $226.38 | 2024-2025 | |
| Astellas Pharma US INC | $181.58 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $161.39 | 2023-2025 | |
| Amgen INC. | $158.07 | 2024-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $120.51 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $105.83 | 2024-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.68 | 2024-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $80.55 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $59.82 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.72 | 2025 | Xifaxan |
| Corcept Therapeutics | $49.21 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $39.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonia Soper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.